Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
K9 Gold Provides Corporate Update (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Belite Bio Inc BLTE

Healthcare
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on therapeutics targeting untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration (dry AMD) and autosomal recessive Stargardt disease (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:BLTE)

Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results

GlobeNewswire August 8, 2023

Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results

GlobeNewswire August 4, 2023

Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA

GlobeNewswire July 27, 2023

Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease

GlobeNewswire July 24, 2023

Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants

GlobeNewswire May 30, 2023

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants

GlobeNewswire May 30, 2023

Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results

GlobeNewswire May 10, 2023

Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results

GlobeNewswire May 10, 2023

Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data

GlobeNewswire May 4, 2023
View More News ››

Opinion & Analysis (NDAQ:BLTE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:BLTE)

Be the first to post on this bullboard.

Goldshore Resources Inc

Goldshore Resources Inc

Goldshore Resources Inc. is a Canada-based junior gold development company. The Company is focused on the acquisition and ...
View More »